LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanopatterned Microfluidic Chip Detects Cancer Markers

By LabMedica International staff writers
Posted on 13 Mar 2019
Image: The three-dimensional (3D) herringbone nanopatterned microfluidic chip that detects cancer faster (Photo courtesy of the University of Kansas).
Image: The three-dimensional (3D) herringbone nanopatterned microfluidic chip that detects cancer faster (Photo courtesy of the University of Kansas).
The performance of current microfluidic methods for exosome detection is constrained by boundary conditions, as well as fundamental limits to microscale mass transfer and interfacial exosome binding.

Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule amounts of blood. A device, which is called a "3D-nanopatterned microfluidic chip," could successfully detect cancer markers in the tiniest drop of blood or in a component of the blood called plasma.

Biochemists at the University of Kansas (Lawrence, KS, USA) and their colleagues have shown that a microfluidic chip designed with self-assembled three-dimensional herringbone nanopatterns can detect low levels of tumor-associated exosomes in plasma (10 exosomes μL−1, or approximately 200 vesicles per 20 μL of spiked sample) that would otherwise be undetectable by standard microfluidic systems for biosensing. The nanopatterns promote microscale mass transfer, increase surface area and probe density to enhance the efficiency and speed of exosome binding, and permit drainage of the boundary fluid to reduce near-surface hydrodynamic resistance, thus promoting particle–surface interactions for exosome binding.

The scientists used the device for the detection, in 2 μL plasma samples from 20 ovarian cancer patients and 10 age-matched controls, of exosome subpopulations expressing CD24, epithelial cell adhesion molecule and folate receptor alpha proteins. They suggest exosomal folate receptor alpha as a potential biomarker for early detection and progression monitoring of ovarian cancer. The nanolithography-free nanopatterned device should facilitate the use of liquid biopsies for cancer diagnosis.

Yong Zeng, PhD, an associate professor of chemistry and the senior author of the study, said, “Historically, people thought exosomes were like 'trash bags' that cells could use to dump unwanted cellular contents. But, in the past decade scientists realized they were quite useful for sending messages to recipient cells and communicating molecular information important in many biological functions. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are really active compared to normal cells.” The study was published on February 25, 2019, in the journal Nature Biomedical Engineering.

Related Links:
University of Kansas

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more